AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15819377 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (dietary changes, physical exercise, weight control)
Number of subjects: 100
Study 15819377 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatments (glycaemia treatment, lipidaemia treatment, blood pressure lowering, platelet aggregation inhibitors)
Number of subjects: 100
Study 15819377 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial treatment (open randomised trial)
Number of subjects: 100
Study 11487422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue Exposure Treatment (CET)
Number of subjects: 100
Study 11487422 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST)
Number of subjects: 100
Study 11487422 — intervention group
Group type: EXPERIMENTAL
Intervention: CET
Number of subjects: 100
Study 11487422 — intervention group
Group type: EXPERIMENTAL
Intervention: CET and CST
Number of subjects: 100
Study 11487422 — intervention group
Group type: EXPERIMENTAL
Intervention: CST
Number of subjects: 100
Study 11487422 — intervention group
Group type: EXPERIMENTAL
Intervention: Urge-specific strategies taught in CET
Number of subjects: 100
Study 11487422 — intervention group
Group type: COMPARATOR
Intervention: Meditation-relaxation control
Number of subjects: 100
Study 11487422 — intervention group
Group type: COMPARATOR
Intervention: Education control
Number of subjects: 100
Study 9571355 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4-8 mg daily)
Number of subjects: 26
Study 9571355 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25-50 mg daily)
Number of subjects: 26
Study 9571355 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 nondiabetic nonhypertensive subjects)
Number of subjects: 26
Study 7829413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone-sulbactam
Number of subjects: 76
Study 7829413 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin plus gentamicin
Number of subjects: 76
Study 7829413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 76
Study 7829413 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 76
Study 2905151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 0
Study 2905151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 50 mg
Number of subjects: 0
Study 2905151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31478415 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF supplementation (0.6 ng/mL)
Number of subjects: 631
Study 31478415 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 631
Study 29408333 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine
Number of subjects: 22603
Study 29408333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22603
Study 27382685 — intervention group
Group type: COMPARATOR
Intervention: Manipulative reduction
Number of subjects: 132
Study 27382685 — intervention group
Group type: EXPERIMENTAL
Intervention: TRV-CRP
Number of subjects: 132
Study 27382685 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 132
Study 25245814 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (GABABR agonist)
Number of subjects: 0
Study 25245814 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (positive modulator at GABAARs)
Number of subjects: 0
Study 25245814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21254867 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% clindamycin phosphate gel applied twice daily and 0.1% adapalene gel applied once daily for 4 weeks (initial treatment) followed by either OD group (adapalene applied once daily) or TW group (adapalene applied once daily on 2 days per week) for 4 weeks (maintenance phase)
Number of subjects: 66
Study 20368559 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (given in two divided daily doses for 14 consecutive days of a 21-day cycle for six cycles)
Number of subjects: 161
Study 20368559 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 161
Study 18395398 — intervention group
Group type: EXPERIMENTAL
Intervention: High potency opioids prescribed by primary oncology team
Number of subjects: 131
Study 18395398 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Management Index scores
Number of subjects: 131
Study 15974840 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous connective tissue (CT) graft beneath a coronally advanced flap
Number of subjects: 4
Study 15974840 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) graft beneath a coronally advanced flap
Number of subjects: 4
Study 15974840 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap alone
Number of subjects: 4
Study 12867403 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% gel
Number of subjects: 14
Study 12867403 — intervention group
Group type: COMPARATOR
Intervention: Amethocaine 1% eyedrops
Number of subjects: 14
Study 11284783 — intervention group
Group type: EXPERIMENTAL
Intervention: Nabumetone 1 g b.d. by mouth for 2 weeks
Number of subjects: 180
Study 11284783 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg daily for 2 weeks
Number of subjects: 180
Study 11284783 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin or NSAIDs for 2 weeks)
Number of subjects: 180
Study 9261860 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg KDI-792
Number of subjects: 36
Study 9261860 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg KDI-792
Number of subjects: 36
Study 9261860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8501488 — intervention group
Group type: EXPERIMENTAL
Intervention: LSA2L2
Number of subjects: 429
Study 8501488 — intervention group
Group type: COMPARATOR
Intervention: COMP
Number of subjects: 429
Study 3030087 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day, range 10 to 40)
Number of subjects: 40
Study 3030087 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide (5 mg/day, range 2.5 to 10)
Number of subjects: 40
Study 3030087 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 40
Study 3030087 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide
Number of subjects: 40
Study 29984336 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-kinetic (PK) system
Number of subjects: 121
Study 29984336 — intervention group
Group type: COMPARATOR
Intervention: Monopolar system
Number of subjects: 121
Study 27659568 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-coated guidewires
Number of subjects: 235
Study 27659568 — intervention group
Group type: COMPARATOR
Intervention: Non-polymer-coated guidewires
Number of subjects: 235
Study 25623409 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with combined behavioral intervention (CBI)
Number of subjects: 1197
Study 25623409 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone without CBI
Number of subjects: 1197
Study 23080269 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine (Group A)
Number of subjects: 73
Study 23080269 — intervention group
Group type: COMPARATOR
Intervention: 0.02% chlorhexidine with eyelid eversion (Group B)
Number of subjects: 73
Study 23080269 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% chlorhexidine without eyelid eversion (Group C)
Number of subjects: 73
Study 20622370 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate intracavitary radiotherapy (HDR-ICRT) with ovoid separation categorized into < 25 mm
Number of subjects: 6
Study 20622370 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate intracavitary radiotherapy (HDR-ICRT) with ovoid separation categorized into > 36 mm
Number of subjects: 6
Study 20622370 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate intracavitary radiotherapy (HDR-ICRT) with ovoid separation categorized into 26-35 mm
Number of subjects: 6
Study 20622370 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate intracavitary radiotherapy (HDR-ICRT)
Number of subjects: 6
Study 19027431 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-help cognitive-behavioral therapy (CBT)
Number of subjects: 51
Study 19027431 — intervention group
Group type: COMPARATOR
Intervention: Group-based cognitive-behavioral therapy (CBT)
Number of subjects: 51
Study 16797800 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution of active pharmaceutical ingredient (API)
Number of subjects: 0
Study 16797800 — intervention group
Group type: COMPARATOR
Intervention: Capsule formulation
Number of subjects: 0
Study 14624167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure measurement (ABPM) on the night of measurement
Number of subjects: 12
Study 14624167 — intervention group
Group type: COMPARATOR
Intervention: Control night (no ABPM)
Number of subjects: 12
Study 14624167 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure measurement (ABPM)
Number of subjects: 12
Study 10922451 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 J
Number of subjects: 100
Study 10922451 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 J
Number of subjects: 100
Study 10922451 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 J
Number of subjects: 100
Study 8931218 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy with limited lymph node dissection (R1+, R2)
Number of subjects: 20
Study 8931218 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy with extensive lymph node dissection (R3)
Number of subjects: 20
Study 8931218 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic-assisted colectomy
Number of subjects: 20
Study 31080627 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Spirit Nurture intervention
Number of subjects: 0
Study 31080627 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 28931531 — intervention group
Group type: EXPERIMENTAL
Intervention: SMC+LP
Number of subjects: 100
Study 28931531 — intervention group
Group type: COMPARATOR
Intervention: SMC
Number of subjects: 100
Study 27578808 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 1012
Study 27578808 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1012
Study 25046061 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention to improve antiretroviral adherence
Number of subjects: 110
Study 25046061 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 110
Study 22659666 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 168
Study 22659666 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 168
Study 18841747 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (suture only on the attached gum)
Number of subjects: 20
Study 18841747 — intervention group
Group type: COMPARATOR
Intervention: Control group (complete suture on free and attached gums)
Number of subjects: 20
Study 16527711 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirrored training boxes (experimental cohort)
Number of subjects: 26
Study 16527711 — intervention group
Group type: COMPARATOR
Intervention: Video‐endoscopic laboratory (control cohort)
Number of subjects: 26
Study 12560300 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg x kg(‐1)) with propofol (2.5 mg x kg(‐1))
Number of subjects: 160
Study 12560300 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg x kg(‐1)) with propofol (2.0 mg x kg(‐1))
Number of subjects: 160
Study 12560300 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg x kg(‐1)) with propofol (1.5 mg x kg(‐1))
Number of subjects: 160
Study 12560300 — intervention group
Group type: COMPARATOR
Intervention: Propofol (2.5 mg x kg(‐1)) without atracurium
Number of subjects: 160
Study 11164075 — intervention group
Group type: COMPARATOR
Intervention: Pharmacia‐Upjohn 15‐mg, 16‐h patch
Number of subjects: 25
Study 11164075 — intervention group
Group type: COMPARATOR
Intervention: Novartis 21‐mg, 24‐h patch
Number of subjects: 25
Study 11164075 — intervention group
Group type: EXPERIMENTAL
Intervention: Alza 21‐mg, 24‐h patch
Number of subjects: 25
Study 9302344 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (50‐100 mg/day)
Number of subjects: 31
Study 9302344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8362641 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified grid laser photocoagulation
Number of subjects: 42
Study 8362641 — intervention group
Group type: COMPARATOR
Intervention: Natural course of the disease (Control)
Number of subjects: 42
Study 3098118 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 24
Study 3098118 — intervention group
Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 24
Study 29655829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 8399
Study 29655829 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8399
Study 27080767 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine 100 mg/day
Number of subjects: 200
Study 27080767 — intervention group
Group type: EXPERIMENTAL
Intervention: entecavir 0.5 mg/day
Number of subjects: 200
Study 27080767 — intervention group
Group type: COMPARATOR
Intervention: standard of care (no anti-viral therapy)
Number of subjects: 200
Study 24755993 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 126
Study 24755993 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 126
Study 22423353 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 40
Study 22423353 — intervention group
Group type: COMPARATOR
Intervention: Placebo attention training (identical stimuli to ABM)
Number of subjects: 40
Study 22423353 — intervention group
Group type: COMPARATOR
Intervention: Placebo attention training (neutral stimuli)
Number of subjects: 40
Study 20720257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine supplementation (1 g lysine/d)
Number of subjects: 271
Study 18519919 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 63‐2521 (0.25‐5 mg)
Number of subjects: 58
Study 18519919 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 63‐2521 (1 mg)
Number of subjects: 58
Study 18519919 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 63‐2521 (5 mg)
Number of subjects: 58
Study 18519919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 18519919 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY 63‐2521
Number of subjects: 58
Study 16154547 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant naive (AN) MDD subjects
Number of subjects: 71
Study 16154547 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 71
Study 16154547 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with antidepressant exposure (AE)
Number of subjects: 71
Study 12854277 — intervention group
Group type: EXPERIMENTAL
Intervention: Semont's maneuver
Number of subjects: 40
Study 12854277 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study 10740941 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol expectancy priming
Number of subjects: 0
Study 10740941 — intervention group
Group type: COMPARATOR
Intervention: Positive mood induction (using positive music)
Number of subjects: 0
Study 10740941 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood induction (using neutral music)
Number of subjects: 0
Study 10740941 — intervention group
Group type: COMPARATOR
Intervention: Neutral words (memory priming)
Number of subjects: 0
Study 8609836 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg/d for 5 days)
Number of subjects: 0
Study 1576049 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI2 5 ng kg‐1 min‐1 for 6 h daily, 5 days a week for 5 weeks
Number of subjects: 36
Study 1576049 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI2 5 ng kg‐1 min‐1 for 6 h daily, 5 days a week for 5 weeks + molsidomine 12 mg daily
Number of subjects: 36
Study 1576049 — intervention group
Group type: COMPARATOR
Intervention: Molsidomine 12 mg daily
Number of subjects: 36
Study 3903336 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodide treatment (200 micrograms/day orally)
Number of subjects: 155
Study 3903336 — intervention group
Group type: COMPARATOR
Intervention: Control group (no iodide treatment)
Number of subjects: 155
Study 29273913 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training program
Number of subjects: 14
Study 29273913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 14
Study 27350113 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CHG) disinfection devices installed on ships
Number of subjects: 347
Study 25623291 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d)
Number of subjects: 25875
Study 25623291 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 FA (1g/d)
Number of subjects: 25875
Study 25623291 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d) and Omega-3 FA (1g/d)
Number of subjects: 25875
Study 25623291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25875
Study 23352800 — intervention group
Group type: EXPERIMENTAL
Intervention: NETA/EE-24
Number of subjects: 32
Study 23352800 — intervention group
Group type: EXPERIMENTAL
Intervention: NETA/EE-21
Number of subjects: 32
Study 21918216 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake of 756 mg Ca/d
Number of subjects: 42
Study 21918216 — intervention group
Group type: COMPARATOR
Intervention: Additional 650 mg Ca/d from dairy or calcium carbonate supplements
Number of subjects: 42
Study 17548211 — intervention group
Group type: EXPERIMENTAL
Intervention: Laterality effect observed in the processing of automatic numerical information
Number of subjects: 0
Study 17548211 — intervention group
Group type: COMPARATOR
Intervention: Control for numerical distance effect
Number of subjects: 0
Study 16971638 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T MR imaging
Number of subjects: 40
Study 16971638 — intervention group
Group type: COMPARATOR
Intervention: 1.5T MR imaging
Number of subjects: 40
Study 12895159 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (doctors involved in drafting and implementing CPGs)
Number of subjects: 723
Study 12895159 — intervention group
Group type: COMPARATOR
Intervention: Control group (doctors not involved in drafting and implementing CPGs)
Number of subjects: 723
Study 10704711 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/ifosfamide
Number of subjects: 0
Study 10704711 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine/ifosfamide
Number of subjects: 0
Study 9093724 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC 100 (epirubicin 100 mg/m2)
Number of subjects: 456
Study 9093724 — intervention group
Group type: COMPARATOR
Intervention: FEC 50 (epirubicin 50 mg/m2)
Number of subjects: 456
Study 8245325 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg once daily)
Number of subjects: 300
Study 8245325 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumadin
Number of subjects: 300
Study 8245325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 8245325 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (in lesions with < 90% stenosis)
Number of subjects: 300
Study 8245325 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumadin (in lesions with < 90% stenosis)
Number of subjects: 300
Study 8245325 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in lesions with < 90% stenosis)
Number of subjects: 300
Study 8245325 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (in complex lesions)
Number of subjects: 300
Study 8245325 — intervention group
Group type: EXPERIMENTAL
Intervention: Coumadin (in complex lesions)
Number of subjects: 300
Study 8245325 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in complex lesions)
Number of subjects: 300
Study 8245325 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenosis severity > 90%
Number of subjects: 300
Study 3510650 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg and cow's milk exclusion diet
Number of subjects: 40
Study 3510650 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 40
Study 31592825 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with 50 s.U ABO
Number of subjects: 0
Study 31592825 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with ≤1 mL HA filler
Number of subjects: 0
Study 31592825 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with ≤50 s.U ABO, ≤2 mL HA filler, and ≤1 mL RSB
Number of subjects: 0
Study 31747862 — intervention group
Group type: EXPERIMENTAL
Intervention: rs12143842 (in the NOS1AP locus)
Number of subjects: 2282
Study 31747862 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis
Number of subjects: 2282
Study 27282797 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT)
Number of subjects: 40
Study 27282797 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 24970885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 1200 mg/d
Number of subjects: 169
Study 24970885 — intervention group
Group type: COMPARATOR
Intervention: Control group (RAS inhibitors only)
Number of subjects: 169
Study 23652031 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone cream (80 mg applied daily for 14 days)
Number of subjects: 10
Study 23652031 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone gel (80 mg applied daily for 14 days)
Number of subjects: 10
Study 23652031 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone cream
Number of subjects: 10
Study 23652031 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone gel
Number of subjects: 10